(KURE) KraneShares MSCI All China - Ratings and Ratios

KraneShares MSCI All China Health Care Index ETF (NYSE ARCA: KURE) is designed to track the performance of the MSCI All China Health Care Index, subject to the 10/40 Constraint. The fund invests at least 80% of its net assets in securities from its underlying index or in instruments with similar economic characteristics. The index is a free-float adjusted, market capitalization-weighted index that measures the equity performance of Chinese companies in the healthcare sector. The 10/40 Constraint caps the weight of the largest stocks in the index at 10% and limits the aggregate weight of all stocks with weights exceeding 5% to no more than 40% of the index. The fund is classified as non-diversified, meaning it may concentrate its investments in a smaller number of securities.

As of the latest data, KURE has an average 20-day trading volume of 254,541 shares, with a last price of $15.03. Its short-term trend indicators show an SMA 20 of $14.87, while its SMA 50 and SMA 200 are $14.33 and $14.48, respectively, signaling a bullish crossover in the near term. The ATR of 0.29 reflects relatively low volatility. With an AUM of $99.27 million, the fund operates with modest assets under management, which may impact liquidity and tracking efficiency.

3-Month Forecast (Based on Technical and Fundamental Data): - Technical Outlook: The funds short-term moving averages (SMA 20 and SMA 50) are trending upward, suggesting potential gains in the near term. However, the tight range between the SMA 20 and SMA 50 indicates limited upside momentum. - Fundamental Outlook: The healthcare sector in China is expected to see steady growth driven by demographic trends and policy support. However, the funds small AUM and relatively low trading volume may lead to higher tracking error and volatility. - Risk Factors: Investors should monitor the impact of the 10/40 Constraint on portfolio concentration and the potential for liquidity challenges due to the funds smaller size.